Inquiry

Hemolysis Evaluation

Hemolysis is a very serious manifestation of drug toxicity. Our company has extensive expertise in local toxicity evaluation, particularly in hemolysis evaluation. We employ talented and highly trained scientists who focus on every aspect of rare disease therapy research and development and have the capabilities and resources to provide a one-stop and customized hemolysis evaluation service.

Overview of Hemolysis Evaluation

Hemolysis refers to reactions such as hemolysis and red blood cell aggregation caused by drug preparations. Hemolysis occurs by two mechanisms, namely toxic hemolysis and allergic hemolysis. All injections and other topical pharmaceutical preparations that may cause immune hemolysis or non-immune hemolysis should undergo hemolysis evaluation. The purpose of drug hemolysis evaluation is to determine the impact of drugs or related preparations on the activities of red blood cells, the complement system, coagulation factors, and various enzymes in the blood by observing whether hemolysis occurs and its extent.

Types of Hemolysis

Our Services

With the world-leading preclinical rare disease research platform, our company provides professional hemolysis evaluation services. Our team will customize the experimental design for your project according to your specific requirements.

We use in vitro test tube method to evaluate the hemolysis of drugs, comparative studies with marketed preparations of the same route of administration, and in vivo tests in animals or combined with repeated drug toxicity tests. The related indexes of hemolytic reaction (reticulocyte, red blood cell count, bilirubin, urine protein, changes of kidney, spleen, and liver, etc.) were observed.

• In vivo hemolytic evaluation
  Over the years, our company has been committed to the construction of an animal model platform that can provide a variety of species for in vivo hemolysis evaluation.

• In vitro hemolytic evaluation
  With the capability of multiple in vitro evaluation methods, in vitro hemolysis evaluation is performed by assessing hemoglobin release.

Why Choose Us?

• Fast and cost-efficient workflow
• Providing standardized upstream platform solutions
• Cost-effective compared to other companies
• Careful design and transparent operation process
• High data quality and reliable analysis
• Exceptional post-sales support

Project Workflow

With a research team with extensive expertise in hemolysis evaluation, our company provides professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your rare disease therapy research projects. If you are interested in our services, please feel free to contact us for more information.

Reference

• Mesdaghinia, A., et al. "An in vitro method to evaluate hemolysis of human red blood cells (RBCs) treated by airborne particulate matter (PM10)." MethodsX 6 (2019): 156-161.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Allergy Evaluation
• Irritation Evaluation